800
Participants
Start Date
August 30, 2023
Primary Completion Date
April 30, 2028
Study Completion Date
August 31, 2028
CHIKV VLP vaccine booster
CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP) 40mg, aluminum hydroxide 2% adjuvant, and formulation buffer supplied as a single dose of 0.8 mL in a pre-filled syringe, to be administered via intramuscular (IM) injection in the deltoid muscle.
Placebo booster
Placebo is comprised of formulation buffer supplied as a single dose of 0.8 mL in a pre-filled syringe administered via IM injection in the deltoid muscle.
Rochester Clinical Research, LLC, Rochester
Alliance for Multispecialty Research, LLC, Norfolk
M3 Wake Research Inc., Raleigh
Optimal Research, LLC, Melbourne
Suncoast Research Associates, LLC, Miami
Alliance for Multispecialty Research, LLC, Mobile
Alliance for Multispecialty Research, LLC, Lexington
Velocity Clinical Research, Cleveland, Cleveland
Synexus Clinical Research US, Inc., Chicago
Optimal Research, LLC, Peoria
Alliance for Multispecialty Research, LLC, Kansas City
Alliance for Multispecialty Research, LLC, Newton
Alliance for Multispecialty Research, LLC, Wichita
Lynn Institute of Norman, Norman
DM Clinical Research, Houston
DM Clinical Research, Tomball
BFHC Research, LLC, San Antonio
Velocity Clinical Research, Austin, Cedar Park
Velocity Clinical Research, Salt Lake City, West Jordan
Alliance for Multispecialty Research, LLC, Tempe
Wr-Crcn, Llc, Las Vegas
Alliance for Multispecialty Research, LLC, Las Vegas
Velocity Clinical Research, Medford, Medford
Velocity Clinical Research, Providence, East Greenwich
Lead Sponsor
Bavarian Nordic
INDUSTRY